Biogen Inc., of Cambridge, Mass., said it joined the Centre for Therapeutic Target Validation (CTTV), a public-private collaboration to improve the success rate for discovering new medicines. The CTTV fosters ongoing interactions between academic and industry members for the purpose of developing open, transformative approaches to selecting and validating novel targets in drug development. The company said its new membership follows the launch of the CTTV target validation platform, which helps researchers identify therapeutic targets for new medicines.